Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Middle East Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report by Product (Traditional API, HP-API, Biologics) by Synthesis (Synthetic, Biotech), Drug, Application, Workflow, and Region with Growth Forecasts, 2025-2033" report has been added to ResearchAndMarkets.com's offering.
The Middle East active pharmaceutical ingredient CDMO market size was estimated at USD 7.54 Billion in 2025 and is projected to reach USD 11.64 billion by 2033, growing at a CAGR of 5.58% from 2025 to 2033.
The market is driven by the growing prevalence of chronic diseases, a focus on generic and biosimilar drugs, and significant technological advancements. Supportive government policies, investment in pharmaceutical infrastructure, and streamlined regulatory processes further stimulate domestic and international players to expand operations in the region.
In addition, the shifting preference of pharmaceutical companies toward outsourcing complex manufacturing processes rather than investing heavily in in-house capabilities is also one of the factors contributing to the market growth. Outsourcing these activities helps pharmaceutical companies to focus more resources on innovation, clinical research, and market expansion. These factors reduce financial risks, shorten development timelines, and allow for faster scalability, which is particularly valuable in a region where healthcare demand is rising rapidly. Furthermore, global players are showing increasing interest in entering the Middle Eastern market due to its strategic geographic location, which offers access to both developed and emerging economies, making it an attractive hub for pharmaceutical trade and distribution.
Furthermore, increasing government initiatives aimed at strengthening local drug manufacturing to ensure regional supply security are also one of the factors fueling the market growth. Several countries in the region are prioritizing domestic production capabilities to reduce dependence on imports and improve access to essential medicines. This has opened opportunities for CDMOs that can provide advanced technologies and regulatory expertise to support local firms. In parallel, a growing number of collaborations and joint ventures between multinational pharmaceutical companies and regional players are accelerating knowledge transfer and boosting overall manufacturing capacity.
Middle East Active Pharmaceutical Ingredient CDMO Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the Middle East active pharmaceutical ingredient CDMO market report based on product, synthesis, drug, application, workflow, and country.
Companies Featured
The leading players profiled in this Middle East Active Pharmaceutical Ingredient CDMO market report include:
- Cambrex Corporation
- Recipharm AB
- Thermo Fisher Scientific Inc.
- CordenPharma International
- Samsung Biologics
- Lonza
- Catalent, Inc
- Siegfried Holding AG
- Piramal Pharma Solutions
- Boehringer Ingelheim International GmbH
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value (USD) in 2025 | $7.54 Billion |
| Forecasted Market Value (USD) by 2033 | $11.64 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Middle East |
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Middle East Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Supply Chain Analysis
3.6. Market Analysis Tools
Chapter 4. Middle East Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Active Pharmaceutical Ingredient CDMO Market Product Movement Analysis
4.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.5. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.6. Biologics
Chapter 5. Middle East Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East Active Pharmaceutical Ingredient CDMO Market: Synthesis Movement Analysis
5.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Synthesis, 2021 to 2033
5.4. Synthetic
5.5. Biotech
Chapter 6. Middle East Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East Active Pharmaceutical Ingredient CDMO Market Drug Movement Analysis
6.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033
6.4. Innovative
6.5. Generics
Chapter 7. Middle East Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Middle East Active Pharmaceutical Ingredient CDMO Market Application Movement Analysis
7.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Application, 2021 to 2033
7.4. Oncology
7.5. Hormonal
7.6. Glaucoma
7.7. Cardiovascular disease
7.8. Diabetes
7.9. Others
Chapter 8. Middle East Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Middle East Active Pharmaceutical Ingredient CDMO Market: Workflow Movement Analysis
8.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Workflow, 2021 to 2033
8.4. Clinical
8.5. Commercial
Chapter 9. Middle East Active Pharmaceutical Ingredient CDMO Market: Country Estimates & Trend Analysis
9.1. Regional Market Dashboard
9.2. Regional Market Snapshot
9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
9.4. Saudi Arabia
9.5. UAE
9.6. Kuwait
9.7. Oman
9.8. Qatar
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Company Market Share Analysis, 2024
10.3. Company Profiles
- Cambrex Corporation
- Recipharm AB
- Thermo Fisher Scientific Inc.
- CordenPharma International
- Samsung Biologics
- Lonza
- Catalent, Inc
- Siegfried Holding AG
- Piramal Pharma Solutions
- Boehringer Ingelheim International GmbH
For more information about this report visit https://www.researchandmarkets.com/r/h2idxl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
